Privia Health Group

PRVANASDAQUSD

THESIS ALERT

Email me when the PRVA thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$23.67
−$0.37 (−1.54%)Today 1M +10.35%
After hours$23.670.00%

Updated Nov 12, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$24.04
Prior regular-session close from the quote source.
$23.65–$24.47
Regular-session low and high so far today.
1.3M
Regular-session shares traded · Nov 12, 4:00 PM ET.
Feb 25 projected
Projected for 2027-02-25 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
$18.92–$28.82
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own PRVA if Privia is a cash-generative bet that independent physicians will outsource the complexity of value-based contracting and practice operations to its enablement platform rather than sell into hospitals or insurer-owned groups.

PRVA price history

Latest price$23.67Today−$0.37 (-1.54%)
PRVA +8.38%S&P 500 -2.67%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Privia’s physician-enablement proposition keeps winning practices that want contracting and operating scale without hospital or insurer employment, so provider-market expansion continues to convert into revenue.StrengtheningMateriality: High

    GAAP annual revenue increased from $966.2 million in FY2021 to $2.123 billion in FY2025. If physicians keep choosing Privia, the company has a long runway; if they choose employment or rival platforms, the growth engine stalls before margins can scale.

    Watch: Local hospital systems accelerate physician employment and make independent-practice affiliation less attractive.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual revenue increased from $966.2 million in FY2021 to $2.123 billion in FY2025.

    Open source ↗
  • Privia’s value-based-care and practice-services model produces cash rather than consuming capital because it enables physicians without taking uncontrolled insurer-like medical-cost risk.StrengtheningMateriality: High

    GAAP annual operating cash flow was positive in FY2022, FY2023, FY2024, and FY2025. Cash conversion makes growth fundable and lowers balance-sheet risk; a shift toward poorly priced risk contracts would turn growth into a capital drain.

    Watch: CMS or commercial payers materially lower shared-savings opportunities, benchmarks, or risk-adjustment payments.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating cash flow was positive in FY2022, FY2023, FY2024, and FY2025.

    Open source ↗
  • The centralized technology and operating platform scales across affiliated practices, so incremental growth should increasingly show up as GAAP operating profit rather than only larger gross billings.StrengtheningMateriality: Medium

    GAAP annual operating income improved from a loss of $217.4 million in FY2021 to positive $34.2 million in FY2025. Operating leverage is what turns a physician-network growth story into durable equity value; without it, Privia remains a low-margin healthcare services company.

    Watch: New markets require heavy local staffing, sales, and medical-group infrastructure that prevents centralized platform leverage.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP annual operating income improved from a loss of $217.4 million in FY2021 to positive $34.2 million in FY2025.

    Open source ↗
  • Privia’s cash-rich balance sheet lets it fund market expansion, technology investment, and selective partnerships without being forced into dilutive or debt-financed growth.StrengtheningMateriality: Medium

    Cash was $479.7 million at FY2025 year-end. A strong balance sheet gives management time to build markets through healthcare contracting cycles; if cash is spent poorly or risk contracts absorb capital, strategic optionality shrinks.

    Watch: Management uses cash for overpriced acquisitions or market launches that do not attract physicians and payer contracts.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash was $479.7 million at FY2025 year-end.

    Open source ↗
  • The model must translate network scale into per-share earnings through margin expansion and disciplined equity compensation, not just higher revenue.HoldingMateriality: Medium

    GAAP diluted EPS improved from a loss of $1.83 in FY2021 to positive $0.18 in FY2025. Owners only benefit if growth compounds per share; if stock compensation, dilution, or thin margins absorb the economics, the business can grow while the stock disappoints.

    Watch: Equity compensation or acquisition-related issuance increases the share count faster than operating profit grows.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    GAAP diluted EPS improved from a loss of $1.83 in FY2021 to positive $0.18 in FY2025.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Privia’s physician-enablement proposition keeps winning practices that want contracting and operating scale without hospital or insurer employment, so provider-market expansion continues to convert into revenue. If physicians keep choosing Privia, the company has a long runway; if they choose employment or rival platforms, the growth engine stalls before margins can scale.

Privia’s value-based-care and practice-services model produces cash rather than consuming capital because it enables physicians without taking uncontrolled insurer-like medical-cost risk. Cash conversion makes growth fundable and lowers balance-sheet risk; a shift toward poorly priced risk contracts would turn growth into a capital drain.

The centralized technology and operating platform scales across affiliated practices, so incremental growth should increasingly show up as GAAP operating profit rather than only larger gross billings. Operating leverage is what turns a physician-network growth story into durable equity value; without it, Privia remains a low-margin healthcare services company.

Privia’s cash-rich balance sheet lets it fund market expansion, technology investment, and selective partnerships without being forced into dilutive or debt-financed growth. A strong balance sheet gives management time to build markets through healthcare contracting cycles; if cash is spent poorly or risk contracts absorb capital, strategic optionality shrinks.

The model must translate network scale into per-share earnings through margin expansion and disciplined equity compensation, not just higher revenue. Owners only benefit if growth compounds per share; if stock compensation, dilution, or thin margins absorb the economics, the business can grow while the stock disappoints.

All standing thesis claims
Original report summary

Privia is a cash-generative bet that independent physicians will outsource the complexity of value-based contracting and practice operations to its enablement platform rather than sell into hospitals or insurer-owned groups.

Evidence assessed Nov 12, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Privia Health Group

Where the evidence on Privia Health Group stands: Holding on the latest evidence (Nov 12, 2026). Of its 5 thesis points, 4 strengthening and 1 holding.

Bull case: what the evidence supports

  • Privia’s physician-enablement proposition keeps winning practices that want contracting and operating scale without hospital or insurer employment, so provider-market expansion continues to convert into revenue.

    sec.gov ↗

  • Privia’s value-based-care and practice-services model produces cash rather than consuming capital because it enables physicians without taking uncontrolled insurer-like medical-cost risk.

    sec.gov ↗

  • The centralized technology and operating platform scales across affiliated practices, so incremental growth should increasingly show up as GAAP operating profit rather than only larger gross billings.

    sec.gov ↗

  • Privia’s cash-rich balance sheet lets it fund market expansion, technology investment, and selective partnerships without being forced into dilutive or debt-financed growth.

    sec.gov ↗

  • The model must translate network scale into per-share earnings through margin expansion and disciplined equity compensation, not just higher revenue.

    sec.gov ↗

Bear case: what would count against it

  • Local hospital systems accelerate physician employment and make independent-practice affiliation less attractive.

    sec.gov ↗

  • CMS or commercial payers materially lower shared-savings opportunities, benchmarks, or risk-adjustment payments.

    sec.gov ↗

  • New markets require heavy local staffing, sales, and medical-group infrastructure that prevents centralized platform leverage.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Privia Health Group

12 mo agonow
Trailing daily price. No thesis break has crossed here, so there is no break base rate to project.

No break has crossed Privia Health Group’s thesis. Its break conditions are checked against every new filing as it lands.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    Privia Health Group filed an SEC 8-K on 2026-11-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Director or principal officer change.

    Privia Health Group filed an SEC 8-K on 2026-08-18: Director or principal officer change. It is a dated development that tests the current thesis.

  3. Mixed
    Reported results of operations (earnings release).

    Privia Health Group filed an SEC 8-K on 2026-08-06: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Local hospital systems accelerate physician employment and make independent-practice affiliation less attractive.
  • CMS or commercial payers materially lower shared-savings opportunities, benchmarks, or risk-adjustment payments.
  • New markets require heavy local staffing, sales, and medical-group infrastructure that prevents centralized platform leverage.
  • Management uses cash for overpriced acquisitions or market launches that do not attract physicians and payer contracts.
  • Equity compensation or acquisition-related issuance increases the share count faster than operating profit grows.

PRVA news

Loading headlines…

Financial statements

PRVA income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

PRVA: quick answers

When does Privia Health Group (PRVA) report earnings next?
Privia Health Group's next results are projected for February 25, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 5, 2026. Earnings calendar
What is PRVA's short interest?
As of October 30, 2026, 3.9M PRVA shares were sold short, 3.05% of its shares outstanding, down 22.2% from the count before. At the stock's average daily volume that is 4.5 days to cover. FINRA publishes the count twice a month. PRVA short interest history
Which well-known investors own PRVA?
1 of the 37 well-known funds tracked here reported PRVA shares in their latest 13F filing. By share of the fund's portfolio: Durable Capital Partners, 2.9%. Fund portfolios

PRVA in well-known investors’ portfolios

1 of 37 funds reported PRVA shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Durable Capital Partners2.9%$299M−3.7%Q2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.